| Satoru Ben Kita, PHARMD | |
|
6512 Comstock Ave, Whittier, CA 90601-4103 | |
| (562) 696-1015 | |
| (562) 696-3525 |
| Full Name | Satoru Ben Kita |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 6512 Comstock Ave, Whittier, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013235282 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 28289 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Satoru Ben Kita, PHARMD 6512 Comstock Ave, Whittier, CA 90601-4103 Ph: (562) 696-1015 | Satoru Ben Kita, PHARMD 6512 Comstock Ave, Whittier, CA 90601-4103 Ph: (562) 696-1015 |
News Archive
A team of researchers affiliated with Ludwig Cancer Research and the Karolinska Institutet in Sweden report in the current issue of Nature Methods a dramatically improved technique for analyzing the genes expressed within a single cell - a capability of relevance to everything from basic research to future cancer diagn
More than two-thirds of women and almost three-quarters of men receiving care at Veterans Affairs outpatient facilities in 2000 were overweight – a higher percentage than among the general population – according to a new report in the American Journal of Preventive Medicine.
The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) today awarded a $153 million contract to Cellerant Therapeutics, Inc. of San Carlos, Calif., to continue developing a new way to treat an illness caused by exposure to high levels of ionizing radiation which can damage the body's cells - the type of radiation that would come from a nuclear blast.
Horizon Discovery Group plc, today announced the addition of an arrayed CRISPR knockout screening service for primary human B cells.
Amarillo Biosciences, Inc. (OTCBB: AMAR) today announced that a Phase 2 study of orally administered interferon-alpha for the prevention of influenza and winter colds has reached the midway point. The study in Perth, Australia achieved full target enrollment of 200 subjects and 98% of the subjects remain on study drug. Subjects in the study are receiving a lozenge containing interferon-alpha or a matching placebo once a day for 16 weeks.
› Verified 2 days ago
Lishan Ng, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 11604 Whittier Blvd, Whittier, CA 90601 Phone: 562-695-7416 | |
Elaine Louie, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 14919 Whittier Blvd, Whittier, CA 90605 Phone: 562-945-5641 Fax: 562-693-8458 | |
Jungyeun Kim, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12291 Washington Blvd Ste 101, Whittier, CA 90606 Phone: 562-945-4166 | |
John Richard Anderson Jr., PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12291 Washington Blvd, 500, Whittier, CA 90606 Phone: 562-698-0811 Fax: 562-789-4376 | |
Melody Eun Ra, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 8508 Painter Ave, Whittier, CA 90602 Phone: 562-945-7940 | |
Anh-thu J Nguyen, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12470 Whittier Blvd, Whittier, CA 90602 Phone: 562-907-3509 |